These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17037358)

  • 21. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
    Magano J
    Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
    Dobrovolny HM; Gieschke R; Davies BE; Jumbe NL; Beauchemin CA
    J Theor Biol; 2011 Jan; 269(1):234-44. PubMed ID: 20970433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated treatment for influenza A and B.
    Montalto NJ; Gum KD; Ashley JV
    Am Fam Physician; 2000 Dec; 62(11):2467-76. PubMed ID: 11130232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
    Wutzler P; Kossow KD; Lode H; Ruf BR; Scholz H; Vogel GE;
    J Clin Virol; 2004 Oct; 31(2):84-91. PubMed ID: 15364262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oseltamivir resistance in influenza A (H5N1) infection.
    Gupta RK; Nguyen-Van-Tam JS
    N Engl J Med; 2006 Mar; 354(13):1423-4; author reply 1423-4. PubMed ID: 16571890
    [No Abstract]   [Full Text] [Related]  

  • 26. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.
    Ward P; Small I; Smith J; Suter P; Dutkowski R
    J Antimicrob Chemother; 2005 Feb; 55 Suppl 1():i5-i21. PubMed ID: 15709056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuraminidase inhibitors: progress in the management of influenza.
    Woodhead M; Lavanchy D; Johnston S; Colman P; Fleming D
    Int J Clin Pract; 2000 Nov; 54(9):604-10. PubMed ID: 11220989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.
    Saito R; Sato I; Suzuki Y; Baranovich T; Matsuda R; Ishitani N; Dapat C; Dapat IC; Zaraket H; Oguma T; Suzuki H
    Pediatr Infect Dis J; 2010 Oct; 29(10):898-904. PubMed ID: 20442686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.
    Baz M; Abed Y; Papenburg J; Bouhy X; Hamelin ME; Boivin G
    N Engl J Med; 2009 Dec; 361(23):2296-7. PubMed ID: 19907034
    [No Abstract]   [Full Text] [Related]  

  • 30. [Criteria for the use of anti-influenza agents].
    Kashiwagi S
    Nihon Rinsho; 2003 Nov; 61(11):1963-6. PubMed ID: 14619439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
    Hurt AC; Ho HT; Barr I
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):795-805. PubMed ID: 17140356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of drug-resistant influenza virus: population dynamical considerations.
    Regoes RR; Bonhoeffer S
    Science; 2006 Apr; 312(5772):389-91. PubMed ID: 16627735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
    Kaji M
    Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuraminidase inhibitors for treatment of influenza.
    Ebell MH
    Am Fam Physician; 2004 Jun; 69(12):2824. PubMed ID: 15222647
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuraminidase inhibitors for influenza.
    Moscona A
    N Engl J Med; 2005 Sep; 353(13):1363-73. PubMed ID: 16192481
    [No Abstract]   [Full Text] [Related]  

  • 36. Influenza: evolving strategies in treatment and prevention.
    Lynch JP; Walsh EE
    Semin Respir Crit Care Med; 2007 Apr; 28(2):144-58. PubMed ID: 17458769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antivirals for influenza: where now for clinical practice and pandemic preparedness?
    Nguyen-Van-Tam JS; Openshaw PJ; Nicholson KG
    Lancet; 2014 Aug; 384(9941):386-7. PubMed ID: 24837882
    [No Abstract]   [Full Text] [Related]  

  • 38. Neuraminidase inhibitors for influenza A and B: antivirals need to be protected from adverse conditions to retain effectiveness.
    Arya SC; Agarwal N
    BMJ; 2003 Jul; 327(7406):105-6. PubMed ID: 12855538
    [No Abstract]   [Full Text] [Related]  

  • 39. Environmental resistance development to influenza antivirals: a case exemplifying the need for a multidisciplinary One Health approach including physicians.
    Järhult JD
    Acta Vet Scand; 2018 Jan; 60(1):6. PubMed ID: 29370857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza antivirals and resistance: the next 10 years?
    Hurt AC; Butler J; Kelso A; Barr IG
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1221-3. PubMed ID: 23241176
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.